China Medical University and Hospital Researcher Provides Details of New Studies and Findings in the Area of Retinopathy of Prematurity [Six years follow-up of type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of...].

A recent study conducted at China Medical University and Hospital in Taichung, Taiwan, investigated the biometric and refractive outcomes in patients with type 1 retinopathy of prematurity (ROP) who were treated with intravitreal injection (IVI) of ranibizumab (R) and bevacizumab (B) at the age of 6. The study included 60 eyes from 34 patients, with 34 eyes receiving B and 26 eyes receiving R injections. The results showed that at the age of 6, the eyes treated with IVI of R had deeper anterior chamber depth (ACD) and thinner lens thickness (LT) compared to the eyes treated with B. The refractive errors did not differ significantly between the two groups at this age. The study also found that the incidence of high myopia was similar between the two groups at the age of 6, which was different from the outcomes observed at younger ages. This research provides valuable insights into the long-term outcomes of intravitreal injection in type 1 ROP. [Extracted from the article]